Stock listing
NASDAQ:GENB Generate Biomedicines, Inc. Stock
Home listing (NASDAQ) of Generate Biomedicines, Inc.
Follow Generate Biomedicines, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:GENB
$9.54 USD -0.84 (-8.1%)
Close on Nov 20, 2026
- Day range
- $9.40 – $10.58 USDNov 20, 2026
- Volume
- 967,195 sharesNov 20, 2026
- Market cap
- $1.22B USDAt the close on Nov 20, 2026 · price × 128.4M shares outstanding
- Traded on an average day
- $18.61M USDMedian day 1.01M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GENB · Home | $9.54 USD | -0.84 (-8.1%) | 967,195 | $10.06 | $10.58 | $9.40 | $10.38 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GENB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $9.54 | -0.84 | -8.1% | $10.06 | $10.58 | $9.40 | 967,195 | |
| $10.38 | +0.54 | +5.5% | $9.87 | $10.52 | $9.68 | 1,049,406 | |
| $9.84 | -0.65 | -6.2% | $10.40 | $10.81 | $9.73 | 868,031 | |
| $10.49 | -1.58 | -13.1% | $11.90 | $12.14 | $10.38 | 1,315,499 | |
| $12.07 | -0.50 | -4.0% | $12.64 | $12.69 | $11.77 | 797,974 | |
| $12.57 | -0.92 | -6.8% | $12.56 | $13.33 | $11.50 | 1,608,135 | |
| $13.49 | -0.29 | -2.1% | $14.00 | $14.00 | $13.48 | 454,783 | |
| $13.78 | -0.40 | -2.8% | $13.86 | $14.55 | $13.60 | 529,861 | |
| $14.18 | +1.12 | +8.6% | $13.25 | $14.38 | $12.93 | 666,838 | |
| $13.06 | +0.49 | +3.9% | $12.90 | $13.17 | $12.47 | 632,115 | |
| $12.57 | -1.59 | -11.2% | $14.00 | $14.11 | $12.46 | 1,296,730 | |
| $14.16 | +0.31 | +2.2% | $14.27 | $14.34 | $13.40 | 636,267 | |
| $13.85 | +0.64 | +4.8% | $13.33 | $14.17 | $13.33 | 723,832 | |
| $13.21 | -1.25 | -8.6% | $14.28 | $14.64 | $13.18 | 744,521 | |
| $14.46 | -1.31 | -8.3% | $14.80 | $15.63 | $14.25 | 1,168,424 | |
| $15.77 | +0.39 | +2.5% | $15.45 | $16.46 | $15.32 | 1,740,905 | |
| $15.38 | +2.17 | +16.4% | $13.89 | $15.39 | $13.71 | 3,923,327 | |
| $13.21 | +0.86 | +7.0% | $12.35 | $13.39 | $12.20 | 740,237 | |
| $12.35 | -0.06 | -0.5% | $12.52 | $12.55 | $12.21 | 340,815 | |
| $12.41 | -0.38 | -3.0% | $12.75 | $12.94 | $12.20 | 295,554 | |
| $12.79 | -0.32 | -2.4% | $13.00 | $13.37 | $12.54 | 498,911 | |
| $13.11 | +0.21 | +1.6% | $13.04 | $13.21 | $12.80 | 421,212 | |
| $12.90 | +0.34 | +2.7% | $12.53 | $13.07 | $12.44 | 523,325 | |
| $12.56 | +0.47 | +3.9% | $12.20 | $12.85 | $12.12 | 675,260 | |
| $12.09 | -0.97 | -7.4% | $13.02 | $13.22 | $11.84 | 1,074,700 | |
| $13.06 | +0.54 | +4.3% | $12.53 | $13.16 | $12.43 | 974,900 | |
| $12.52 | +0.26 | +2.1% | $12.61 | $12.90 | $12.10 | 1,951,000 | |
| $12.26 | -1.58 | -11.4% | $13.75 | $13.75 | $12.25 | 930,700 | |
| $13.84 | -0.50 | -3.5% | $14.34 | $14.37 | $13.81 | 675,900 | |
| $14.34 | +0.35 | +2.5% | $14.06 | $14.86 | $13.94 | 903,100 | |
| $13.99 | +0.42 | +3.1% | $13.50 | $14.14 | $13.08 | 1,155,700 | |
| $13.57 | -0.23 | -1.7% | $13.59 | $13.99 | $13.35 | 926,300 | |
| $13.80 | -0.11 | -0.8% | $14.00 | $14.19 | $13.55 | 1,169,800 | |
| $13.91 | +0.22 | +1.6% | $13.71 | $14.06 | $13.45 | 1,119,600 | |
| $13.69 | -0.11 | -0.8% | $13.93 | $14.30 | $13.30 | 1,262,600 | |
| $13.80 | -1.22 | -8.1% | $14.79 | $14.99 | $13.77 | 1,391,800 | |
| $15.02 | -0.40 | -2.6% | $15.54 | $15.61 | $15.00 | 733,200 | |
| $15.42 | +0.51 | +3.4% | $14.90 | $15.51 | $14.65 | 594,600 | |
| $14.91 | -0.24 | -1.6% | $15.15 | $15.32 | $14.61 | 1,135,300 | |
| $15.15 | -0.84 | -5.3% | $16.04 | $16.10 | $15.03 | 1,266,700 | |
| $15.99 | -0.53 | -3.2% | $16.44 | $16.48 | $15.40 | 1,438,100 | |
| $16.52 | -0.94 | -5.4% | $17.44 | $17.59 | $16.46 | 1,424,700 | |
| $17.46 | +0.08 | +0.5% | $17.68 | $17.97 | $17.32 | 1,306,100 | |
| $17.38 | +0.24 | +1.4% | $17.46 | $17.68 | $17.11 | 1,393,700 | |
| $17.14 | +0.02 | +0.1% | $17.17 | $17.30 | $16.53 | 1,402,900 | |
| $17.12 | +1.44 | +9.2% | $16.04 | $17.83 | $16.04 | 2,204,800 | |
| $15.68 | -0.51 | -3.2% | $16.09 | $16.40 | $15.61 | 1,509,100 | |
| $16.19 | +0.19 | +1.2% | $15.83 | $16.27 | $15.55 | 959,200 | |
| $16.00 | +0.28 | +1.8% | $15.73 | $16.45 | $15.39 | 1,533,400 | |
| $15.72 | +0.33 | +2.1% | $15.44 | $15.88 | $15.32 | 666,000 | |
| $15.39 | -0.13 | -0.8% | $15.32 | $16.05 | $15.03 | 1,008,300 | |
| $15.52 | -0.38 | -2.4% | $15.80 | $16.23 | $15.20 | 977,900 | |
| $15.90 | -0.49 | -3.0% | $16.36 | $16.36 | $15.40 | 1,257,800 | |
| $16.39 | +0.05 | +0.3% | $16.39 | $16.62 | $15.98 | 724,700 | |
| $16.34 | +0.06 | +0.4% | $16.40 | $16.59 | $15.97 | 963,900 | |
| $16.28 | +0.49 | +3.1% | $15.75 | $16.78 | $15.69 | 892,500 | |
| $15.79 | +0.52 | +3.4% | $15.12 | $16.01 | $14.93 | 1,048,800 | |
| $15.27 | -0.06 | -0.4% | $15.27 | $15.63 | $14.77 | 1,551,900 | |
| $15.33 | -0.44 | -2.8% | $15.77 | $16.30 | $14.74 | 2,353,200 | |
| $15.77 | -0.37 | -2.3% | $17.11 | $17.47 | $15.71 | 2,856,600 | |
| $16.14 | -4.24 | -20.8% | $20.00 | $20.14 | $15.93 | 3,850,000 | |
| $20.38 | +2.66 | +15.0% | $17.67 | $22.67 | $17.38 | 4,692,301 | |
| $17.72 | +1.60 | +9.9% | $16.67 | $17.99 | $16.03 | 2,500,237 | |
| $16.12 | +0.13 | +0.8% | $16.10 | $16.70 | $15.91 | 830,800 | |
| $15.99 | -0.98 | -5.8% | $16.76 | $16.85 | $15.74 | 952,700 |
- Ticker
- NASDAQ:GENB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 56 slides
Latest news
Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 12, 2026
Closed $12.57 (-6.8%) on Nov 12, 2026
Generate Biomedicines to Participate in November Investor Conferences
Oct 22, 2026
Closed $12.79 (-2.4%) on Oct 22, 2026
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Oct 13, 2026
Closed $12.52 (+2.1%) on Oct 14, 2026
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Oct 1, 2026
Closed $13.80 (-8.1%) on Oct 1, 2026
Generate Biomedicines Inc. to Participate in September Investor Conferences
Sep 8, 2026
Closed $15.90 (-3.0%) on Sep 8, 2026
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $13.89 (-4.1%) on Aug 6, 2026
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 28, 2026
Closed $13.12 (+0.2%) on May 29, 2026
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Closed $13.59 (-11.2%) on May 7, 2026
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Feb 26, 2026
Closed $12.91 (-19.3%) on Feb 27, 2026
Generate Biomedicines, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 9 in all · newest Nov 12, 2026 · oldest 2026
- Decks
- 6 decks · latest October 2026
Where Generate Biomedicines, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GENB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:GENB | BOATS | United States | USD |
| BX Swiss:GENB | BX Swiss | Switzerland | CHF |
| BMV:GENB | BMV | Mexico | MXN |
Valuation
EV/sales 28.1× against a median of 15.4×: 4th lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $895.6M USD
- P/E
- Loss
- EV/sales
- 28.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.2×
- Gross margin
- 100.0%
- Operating margin
- −737.0%
- Net margin
- −637.0%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Generate Biomedicines, Inc. · NASDAQ:GENB | US$1.22B | US$895.6M | n/a | 28.1× | n/a | 3.2× | −637.0% | 0.2× | 1.90 |
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Ocular Therapeutix, Inc. · NASDAQ:OCUL | US$1.23B | US$774.9M | n/a | 15.4× | n/a | 2.8× | −648.6% | 0.2× | 1.35 |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Median of the others | US$1.23B | US$849.9M | 0.9× | 15.4× | 309× | 3.4× | −18.6% | 0.0× | 1.27 |
Forecasts
4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 27.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.44 · 4 analysts
- Revenue, year to Dec 2026
- 24.82M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Nally | Chief Executive Officer |
| Jason Silvers | President & Chief Financial Officer |
| Sean Martin | Chief Legal Officer & General Counsel |
| Daria Hazuda | Senior Vice President, Discovery Strategy |
| Dinesh de Alwis | Senior Vice President, Head of Clinical Drug Development |
| Sahm Nasseri | Senior Vice President, Business Development and Strategy |
| Aarif Khakoo | Chief Scientific Officer |
| Beth Grous | Chief People Officer |
| Gevorg Grigoryan | Co-Founder & Chief Technology Officer |
| Laurie Lee | Chief Medical Officer, Immunology & Inflammation |
| Rupert Vessey | Chief Scientist and Executive Partner |
Board
| Director | Role |
|---|---|
| Noubar Afeyan | Chair of the Board |
| Frances Arnold | Director |
| Jane Mendillo | Director |
| Marsha Fanucci | Director |
| Nancy Simonian | Director |
| Paul Parker | Director |
| Rupert Vessey | Chief Scientist and Executive Partner |
| Stéphane Bancel | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −6.8% |
| Q2 2026 | Aug 6, 2026 · Before open | −4.1% |
| Q1 2026 | May 7, 2026 · Before open | −11.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 56 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 57 slides | October 2026 |
| Investor Presentation (October 2026) | Investor deck | 55 slides | October 2026 |
| Investor Presentation (June 2026) | Investor deck | 51 slides | June 2026 |
| ERS Congress 2025 (Late Breaker) | Conference | 11 slides | 2025 |
| IDWeek 2024 | Conference | 12 slides | October 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$400M · US$16 a share · Goldman Sachs & Co. LLC +4 Dealers: Goldman Sachs & Co. LLC (co-lead), Morgan Stanley (co-lead), Piper Sandler, Guggenheim Securities, Cantor | Feb 27, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Feb 26, 2026.
- Price
- US$16.00 a share
- Shares offered
- 25,000,000 shares of common stock
- Offering size
- US$400 million
- Underwriters' option
- Up to 3,750,000 more shares
- Listing
- GENB on the Nasdaq Global Select Market
- Underwriters
- Goldman Sachs & Co. LLC, Morgan Stanley, Piper Sandler, Guggenheim Securities, Cantor · In the order on the cover
- Shares delivered
- On or about Mar 2, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 23, 2025 |
| Filed publicly | Feb 4, 2026 |
| Amended twice | Newest Feb 23, 2026 |
| Shares registered with an exchange | Feb 24, 2026 |
| Declared effective by the SEC | Feb 26, 2026 |
| Final prospectus, with the price | Feb 27, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 27, 2026 |
| EFFECT · Notice that a registration is effective | Feb 26, 2026 |
| CERT · Exchange's certificate of listing | Feb 26, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 24, 2026 |
| S-1/A · Registration statement, amended | Feb 23, 2026 |
| S-1/A · Registration statement, amended | Feb 13, 2026 |
| S-1 · Registration statement | Feb 4, 2026 |
| DRS · Draft registration statement | Dec 23, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 27, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 31.9M | 20.5M |
| Gross profit | 31.9M | 20.5M |
| Research and development | 224.7M | 175.3M |
| Selling, general and administrative | 42.3M | 42.1M |
| Operating income | -235.1M | -196.9M |
| Depreciation and amortization | 13.2M | 15.3M |
| EBITDA | -221.9M | -181.6M |
| Interest expense | 1.14M | 2.12M |
| Income before tax | -222.8M | -181.2M |
| Income tax | 163.0K | 212.0K |
| Net income | -203.2M | -173.8M |
| Earnings per share, basic | -4.06 | -1.36 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 121.7M | 176.3M |
| Short-term investments | 99.8M | 217.4M |
| Receivables | 0 | 308.0K |
| Current assets | 234.4M | 407.5M |
| Total assets | 330.2M | 518.3M |
| Accounts payable | 3.84M | 5.67M |
| Current liabilities | 82.2M | 86.6M |
| Total debt | 68.5M | 77.0M |
| Total liabilities | 953.4M | 953.3M |
| Shareholders' equity | -616.0M | -434.5M |
| Shares outstanding | 50.1M | 127.5M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -200.6M | -117.8M |
| Capital spending | -3.51M | -3.45M |
| Free cash flow | -204.1M | -121.2M |
| Cash from investing | 116.8M | -57.7M |
| Cash from financing | 28.1M | 91.3M |
| Change in cash | -55.8M | -84.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 25, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
All 58 filings
Cap table
Built by 6ix from Generate Biomedicines, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 128,352,436
- Fully diluted
- 128,352,436
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 128,352,436 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 128,352,436 |
| Sep 30, 2026 | 129,021,869 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Noubar Afeyan Other companies: Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past); Agenus Inc. (Director · Jan 13, 2005 – Jun 7, 2007 · Past) | Chair of the Board · Since at least Feb 26, 2026 |
| Marsha Fanucci Other companies: Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Oct 14, 2022 · Past); Cyclerion Therapeutics, Inc. (Director · Mar 14, 2019 – Jun 14, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 5, 2024 · Past); Alnylam Pharmaceuticals, Inc. (Director · Dec 8, 2010 – May 18, 2023 · Past); Ironwood Pharmaceuticals, Inc. (Director · Feb 2, 2010 – Apr 1, 2019 · Past); Momenta Pharmaceuticals Inc (Director · Jun 15, 2006 – Jun 23, 2016 · Past); Millennium Pharmaceuticals Inc (SVP, Chief Financial Officer · Sep 15, 2005 – May 14, 2008 · Past) | Director · Since at least Feb 26, 2026 |
| Nancy Simonian Other companies: Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 17, 2020 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Dec 2, 2024 · Past); Seagen Inc (Director · Mar 19, 2012 – Dec 14, 2023 · Past); Millennium Pharmaceuticals Inc (Chief Medical Officer · May 31, 2007 – May 14, 2008 · Past); ArQule Inc (Director · May 12, 2006 – May 13, 2010 · Past) | Director · Since at least Feb 26, 2026 |
| Frances Arnold Other companies: Alphabet Inc (Google) Class C (Director · Since at least Dec 31, 2020); Illumina, Inc. (Director · Dec 23, 2020 – May 21, 2025 · Past) | Director · Since at least Feb 26, 2026 |
| Jane Mendillo Other companies: General Motors Company (Director · Jun 7, 2016 – Dec 31, 2021 · Past); Lazard, Inc. (Director · Apr 19, 2016 – Feb 18, 2025 · Past) | Director · Since at least Feb 26, 2026 |
| Michael Nally Other companies: PPG Industries, Inc. (Director · Since at least Feb 18, 2021); Merck & Company, Inc. (EVP, Chief Marketing Officer · Jan 1, 2019 – Feb 26, 2021 · Past) | Chief Executive Officer, Director · Since at least Feb 26, 2026 |
| Rupert Vessey Other companies: Bio-Techne Corp (Director · Since at least Oct 29, 2020); Bristol-Myers Squibb Company (EVP & President, Research · Oct 30, 2020 – May 3, 2023 · Past) | Director · Since at least Feb 26, 2026 |
| Sean Martin Other companies: Baxter International Inc. (SVP and General Counsel · Feb 28, 2017 – Mar 2, 2022 · Past); Apollo Education Group Inc (SVP, General Counsel · Sep 23, 2010 – Feb 1, 2017 · Past) | Chief Legal Officer & General Counsel · Since at least Feb 26, 2026 |
| Stéphane Bancel Other companies: BG Medicine Inc (Executive Chairman of the Board · Since at least Nov 5, 2026); Moderna, Inc. (Chief Executive Officer, Director · Since at least Aug 5, 2026) | Director · Since at least Nov 4, 2026 |
| Paul Parker Other companies: Clorox Company (the) (Director · Nov 18, 2020 – Sep 30, 2024 · Past) | Director · Since at least Feb 26, 2026 |
All 19 people
| Person | Seat |
|---|---|
| Aarif Khakoo | Chief Scientific Officer · Since at least Feb 26, 2026 |
| Beth Grous | Chief People Officer · Since at least Feb 26, 2026 |
| Beth Grous | Chief People Officer · Since at least Nov 4, 2026 |
| Daria Hazuda | Senior Vice President, Discovery Strategy · Since at least Nov 4, 2026 |
| Dinesh de Alwis | Senior Vice President, Head of Clinical Drug Development · Since at least Oct 1, 2026 |
| Gevorg Grigoryan | Co-Founder & Chief Technology Officer · Since at least Feb 26, 2026 |
| Jason Silvers | President & CFO · Since at least Feb 26, 2026 |
| Laurie Lee | Chief Medical Officer, Immunology & Inflammation · Since at least Feb 26, 2026 |
| Sahm Nasseri | Senior Vice President, Business Development and Strategy · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Generate Biomedicines, Inc.